IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0362992
(2012-01-31)
|
등록번호 |
US-8961979
(2015-02-24)
|
발명자
/ 주소 |
- Emery, Daryll A.
- Straub, Darren E.
- Wonderling, Laura
- Herron Olson, Lisa L.
|
출원인 / 주소 |
|
대리인 / 주소 |
Mueting, Raasch & Gebhardt, P.A.
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
33 |
초록
The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
대표청구항
▼
1. A composition comprising: a combination of isolated antibodies that specifically binds at least five polypeptides, each polypeptide having a molecular weight of 88 kDa, 55 kDa, 38 kDa, 37 kDa, 36 kDa, 35 kDa, or 33 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;whe
1. A composition comprising: a combination of isolated antibodies that specifically binds at least five polypeptides, each polypeptide having a molecular weight of 88 kDa, 55 kDa, 38 kDa, 37 kDa, 36 kDa, 35 kDa, or 33 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;wherein the polypeptide having a molecular weight of 88 kDa comprises the amino acid sequences depicted in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 55 kDa comprises the amino acid sequences depicted in SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:58, and SEQ ID NO:59, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 38 kDa comprises the amino acid sequences depicted in SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:76, and SEQ ID NO:77, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 37 kDa comprises the amino acid sequences depicted in SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, and SEQ ID NO:101, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 36 kDa comprises the amino acid sequences depicted in SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, and SEQ ID NO:110, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 35 kDa comprises the amino acid sequences depicted in SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, and SEQ ID NO:124, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl; andwherein the polypeptide having a molecular weight of 33 kDa comprises the amino acid sequences depicted in SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, and SEQ ID NO:143, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl. 2. The composition of claim 1 further comprising a pharmaceutically acceptable carrier. 3. The antibody composition of claim 1 wherein at least one antibody is an antibody fragment. 4. The antibody composition of claim 3 wherein the antibody fragment comprises an scFv, a Fab, a F(ab′)2 or a Fv. 5. A composition comprising: a combination of isolated antibodies that specifically binds to polypeptides having molecular weights of 88 kDa, 55 kDa, 38 kDa, 37 kDa, 36 kDa, 35 kDa, and 33 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;wherein the polypeptide having a molecular weight of 88 kDa comprises the amino acid sequences depicted in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 55 kDa comprises the amino acid sequences depicted in SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:58, and SEQ ID NO:59, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 38 kDa comprises the amino acid sequences depicted in SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:76, and SEQ ID NO:77, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 37 kDa comprises the amino acid sequences depicted in SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, and SEQ ID NO:101, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 36 kDa comprises the amino acid sequences depicted in SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, and SEQ ID NO:110, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 35 kDa comprises the amino acid sequences depicted in SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, and SEQ ID NO:124, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl; andwherein the polypeptide having a molecular weight of 33 kDa comprises the amino acid sequences depicted in SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, and SEQ ID NO:143, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl. 6. The composition of claim 5 further comprising a pharmaceutically acceptable carrier. 7. The antibody composition of claim 5 wherein the at least one antibody is an antibody fragment. 8. The antibody composition of claim 7 wherein the antibody fragment comprises an scFv, a Fab, a F(ab′)2 or a Fv. 9. A composition comprising: a combination of isolated antibodies that specifically binds to: at least two polypeptides, each polypeptide having a molecular weight of 88 kDa, 55 kDa, 35 kDa, or 33 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis; andat least one polypeptide having a molecular weight of 38 kDa, 37 kDa, or 36 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;wherein the polypeptide having a molecular weight of 88 kDa comprises the amino acid sequences depicted in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 55 kDa comprises the amino acid sequences depicted in SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:58, and SEQ ID NO:59, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 38 kDa comprises the amino acid sequences depicted in SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:76, and SEQ ID NO:77, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 37 kDa comprises the amino acid sequences depicted in SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, and SEQ ID NO:101, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 36 kDa comprises the amino acid sequences depicted in SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, and SEQ ID NO:110, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the polypeptide having a molecular weight of 35 kDa comprises the amino acid sequences depicted in SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, and SEQ ID NO:124, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl; andwherein the polypeptide having a molecular weight of 33 kDa comprises the amino acid sequences depicted in SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, and SEQ ID NO:143, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl. 10. The composition of claim 9 further comprising a pharmaceutically acceptable carrier. 11. The antibody composition of claim 9 wherein at least one antibody is an antibody fragment. 12. The antibody composition of claim 11 wherein the antibody fragment comprises an scFv, a Fab, a F(ab′)2 or a Fv. 13. An antibody composition that specifically binds at least one metal regulated polypeptide, the composition prepared by a method comprising: collecting a body fluid from an animal that comprises antibody that specifically binds to at least one metal regulated polypeptide, wherein the animal has been administered a composition comprising: at least five isolated polypeptides, each polypeptide having a molecular weight of 88 kDa, 55 kDa, 38 kDa, 37 kDa, 36 kDa, 35 kDa, or 33 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;wherein each of the five isolated polypeptides specifically binds to an antibody that specifically binds to a reference polypeptide having a molecular weight of 88 kDa, 55 kDa, 38 kDa, 37 kDa, 36 kDa, 35 kDa, or 33 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;wherein the reference polypeptide having a molecular weight of 88 kDa comprises the amino acid sequences depicted in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 55 kDa comprises the amino acid sequences depicted in SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:58, and SEQ ID NO:59, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 38 kDa comprises the amino acid sequences depicted in SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:76, and SEQ ID NO:77, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 37 kDa comprises the amino acid sequences depicted in SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, and SEQ ID NO:101, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 36 kDa comprises the amino acid sequences depicted in SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, and SEQ ID NO:110, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 35 kDa comprises the amino acid sequences depicted in SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, and SEQ ID NO:124, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl; andwherein the reference polypeptide having a molecular weight of 33 kDa comprises the amino acid sequences depicted in SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, and SEQ ID NO:143, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl. 14. The antibody composition of claim 13 further comprising a pharmaceutically acceptable carrier. 15. The antibody composition of claim 13 wherein the isolated polypeptides administered to the animal are from S. aureus ATCC strain 19636. 16. The antibody composition of claim 13 further comprising at least one antibody fragment that specifically binds to a metal regulated polypeptide. 17. The antibody composition of claim 16 wherein the antibody fragment comprises an scFv, a Fab, a F(ab′)2 or a Fv. 18. The antibody composition of claim 13 wherein the animal is an avian, a bovine, a caprine, a porcine, an ovine, a bisontine, a cervine, or a companion animal. 19. The antibody composition of claim 13 comprising antibody that specifically binds to a metal regulated polypeptide present on the surface of a gram positive microbe. 20. The antibody composition of claim 19 wherein the gram positive microbe is a member of the family Micrococcaceae, family Streptococcaceae, family Corynebacteriaceae, or family Mycobacteriaceae. 21. The antibody composition of claim 20 wherein the member of the family Micrococcaceae is Staphylococcus spp. 22. The antibody composition of claim 20 wherein the member of the family Streptococcaceae is Streptococcus spp. 23. The antibody composition of claim 22 wherein the Streptococcus spp. is S. agalactiae, S. uberis, S. bovis, S. equi, S. zooepidemicus, or S. dysgalatiae. 24. The antibody composition of claim 20 wherein the member of the family Corynebacteriaceae is Corynebacterium spp. 25. The antibody composition of claim 20 wherein the member of the family Mycobacteriaceae is Mycobacterium spp. 26. The antibody composition of claim 13 wherein the body fluid comprises serum, plasma, blood, milk, or colostrum. 27. A composition comprising: an isolated body fluid from an animal, or a fraction thereof, comprising antibody that specifically binds to at least five metal regulated polypeptides from a Staphylococcus spp.; anda pharmaceutically acceptable excipient. 28. The composition of claim 27 wherein the body fluid comprises serum, plasma, blood, milk, or colostrum. 29. The composition of claim 27 wherein the animal is an avian, a bovine, a caprine, a porcine, an ovine, a bisontine, a cervine, or a companion animal. 30. The composition of claim 27 comprising antibody that specifically binds to a metal regulated polypeptide present on the surface of a gram positive microbe. 31. The composition of claim 30 wherein the gram positive microbe is a member of the family Micrococcaceae, family Streptococcaceae, Corynebacteriaceae, or family Mycobacteriaceae. 32. The composition of claim 31 wherein the member of the family Micrococcaceae is Staphylococcus spp. 33. The antibody composition of claim 31 wherein the member of the family Streptococcaceae is Streptococcus spp. 34. The composition of claim 33 wherein the Streptococcus spp. is S. agalactiae, S. uberis, S. bovis, S. equi, S. zooepidemicus, or S. dysgalatiae. 35. The composition of claim 31 wherein the member of the family Corynebacteriaceae is Corynebacterium spp. 36. The composition of claim 31 wherein the member of the family Mycobacteriaceae is Mycobacterium spp. 37. The composition of claim 27 wherein the Staphyloccocus spp. is S. aureus ATCC strain 19636. 38. The composition of claim 27 wherein the antibody that specifically binds to at least one metal regulated polypeptide is an antibody fragment. 39. The composition of claim 38 wherein the antibody fragment comprises an scFv, a Fab, a F(ab′)2 or a Fv. 40. An antibody composition that specifically binds at least one metal regulated polypeptide, the composition prepared by a method comprising: collecting a body fluid from an animal that comprises antibody that specifically binds to at least one metal regulated polypeptide, wherein the animal has been administered a composition comprising: whole cells of a Staphylococcus spp. comprising at least five metal regulated polypeptides, each polypeptide having a molecular weight of 88 kDa, 55 kDa, 38 kDa, 37 kDa, 36 kDa, 35 kDa, or 33 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;wherein each of the at least five metal regulated polypeptides specifically binds to an antibody that specifically binds to a reference polypeptide having a molecular weight of 88 kDa, 55 kDa, 38 kDa, 37 kDa, 36 kDa, 35 kDa, or 33 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis;wherein the reference polypeptide having a molecular weight of 88 kDa comprises the amino acid sequences depicted in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, and SEQ ID NO:33, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 55 kDa comprises the amino acid sequences depicted in SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:58, and SEQ ID NO:59, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 38 kDa comprises the amino acid sequences depicted in SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:76, and SEQ ID NO:77, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 37 kDa comprises the amino acid sequences depicted in SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, and SEQ ID NO:101, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 36 kDa comprises the amino acid sequences depicted in SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, and SEQ ID NO:110, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl;wherein the reference polypeptide having a molecular weight of 35 kDa comprises the amino acid sequences depicted in SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, and SEQ ID NO:124, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl; andwherein the reference polypeptide having a molecular weight of 33 kDa comprises the amino acid sequences depicted in SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:140, SEQ ID NO:142, and SEQ ID NO:143, and is expressed by Staphylococcus aureus ATCC strain 19636 at a greater level when grown in medium comprising 2,2-dipyridyl at a concentration of 1600 μM compared to when grown in the medium without the 2,2-dipyridyl. 41. The antibody composition of claim 40 further comprising a pharmaceutically acceptable carrier. 42. The antibody composition of claim 40 wherein the whole cells administered to the animal comprise S. aureus ATCC strain 19636. 43. The antibody composition of claim 40 further comprising at least one antibody fragment that specifically binds to a metal regulated polypeptide. 44. The antibody composition of claim 43 wherein the antibody fragment comprises an scFv, a Fab, a F(ab′)2 or a Fv. 45. The antibody composition of claim 40 wherein the animal is an avian, a bovine, a caprine, a porcine, an ovine, a bisontine, a cervine, or a companion animal. 46. The antibody composition of claim 40 comprising antibody that specifically binds to a metal regulated polypeptide present on the surface of a gram positive microbe. 47. The antibody composition of claim 46 wherein the gram positive microbe is a member of the family Micrococcaceae, family Streptococcaceae, family Corynebacteriaceae, or family Mycobacteriaceae. 48. The antibody composition of claim 47 wherein the member of the family Micrococcaceae is Staphylococcus spp. 49. The antibody composition of claim 47 wherein the member of the family Streptococcaceae is Streptococcus spp. 50. The antibody composition of claim 49 wherein the Streptococcus spp. is S. agalactiae, S. uberis, S. bovis, S. equi, S. zooepidemicus, or S. dysgalatiae. 51. The antibody composition of claim 47 wherein the member of the family Corynebacteriaceae is Corynebacterium spp. 52. The antibody composition of claim 47 wherein the member of the family Mycobacteriaceae is Mycobacterium spp. 53. The antibody composition of claim 40 wherein the body fluid comprises serum, plasma, blood, milk, or colostrum.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.